Market News

NASDAQ:AVXL News

2 stories
tradingview

Anavex Life Sciences reports preliminary Q2 FY2026 net loss $5.3M, cash $127.4M

Anavex Life Sciences reported preliminary results for the fiscal second quarter ended March 31, 2026, posting a net loss of $5.3 million, or $0.06 per share, compared with a $11.2 million loss in the year-ago quarter. Cash and cash equivalents were $127.4 million as of March 31, 2026, and the compa…

TradingView en
StocksUS
tradingview

Anavex Life Sciences submits compliance plan to Nasdaq after 10-Q delay

Anavex Life Sciences submitted a Compliance Plan to Nasdaq to address a late Form 10-Q filing and seek reinstatement of listing compliance.Key Highlights:Original SEC Filing: ANAVEX LIFE SCIENCES CORP. [ AVXL ] - 8-K - Jul. 20, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…

TradingView en
StocksUS